Kiniksa Pharmaceuticals (KNSA) Price & Analysis

Compare

524 Followers

KNSA Stock Chart & Stats

$38.77

$0.18(0.88%)

At close: Jan 08 4:00 PM EST

$38.77

$0.18(0.88%)

Day’s Range― - ―

52-Week Range$17.82 - $39.79

Previous CloseN/A

Volume84.12K

Average Volume (3M)415.95K

Market Cap

$2.88B

Enterprise Value$1.86B

Total Cash (Recent Filing)$307.78M

Total Debt (Recent Filing)$9.77M

Price to Earnings (P/E)946.5

Beta0.68

Next Earnings

Nov 04, 2025

EPS Estimate

0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.23

Shares Outstanding43,472,927

10 Day Avg. Volume440,601

30 Day Avg. Volume415,955

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue3.51

Enterprise Value/Gross Profit4.54

Enterprise Value/Ebitda330.78

Forecast

1Y Price Target

$50.43

Price Target Upside30.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Financial PerformanceKiniksa is at a pivotal stage of the company's lifecycle as it is cash flow positive, has plenty of room to expand Arcalyst's reach, and has a derisked, next-gen asset (KPL-387) to extend the franchise.

Product LaunchArcalyst's launch continues to ramp and KPL-387 could offer more favorable dosing supporting a switch to significantly improve the company's bottom line.

Revenue GrowthSince the March 2021 approval, Arcalyst generated $1B+ of sales driven by 16 consecutive quarters of growth with no signs of slowing.

Bears Say

Market CompetitionThe company's future relies heavily on the successful launch and adoption of KPL-387, which faces competitive challenges in the market.

Operational RisksDespite strong commercial execution, the company's reliance on Arcalyst's growth poses a risk if market dynamics change unfavorably.

Kiniksa Pharmaceuticals News

Kiniksa announces Orphan Drug Designation for KPL-387

Kiniksa (KNSA) Pharmaceuticals announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to KPL-387 for...

7d ago

KNSA

Kiniksa price target raised to $50 from $45 at Citi

Citi analyst Geoff Meacham raised the firm’s price target on Kiniksa (KNSA) to $50 from $45 and keeps...

8d ago

KNSA

Kiniksa granted orphan designation for treatment of pericarditis

Kiniksa (KNSA) Pharmaceuticals was granted FDA orphan designation for its treatment of pericarditis , according to a post...

8d ago

KNSA

Kiniksa price target raised to $44 from $38 at Wedbush

Wedbush raised the firm’s price target on Kiniksa (KNSA) to $44 from $38 and keeps an Outperform rating...

11d ago

KNSA

Kiniksa initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Kiniksa (KNSA) with a Buy rating and $60 price target The firm says...

26d ago

KNSA

Strong Commercial Execution and Growth Potential Drive Buy Rating for Kiniksa Pharmaceuticals

Analyst Nicholas Lorusso of TD Cowen maintained a Buy rating on Kiniksa Pharmaceuticals, retaining the price target of...

3d ago

KNSA

Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline

Kiniksa Pharmaceuticals (KNSA) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler...

26d ago

KNSA

Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth

Kiniksa Pharmaceuticals ( ($KNSA) ) has shared an update. On September 3, 2025, Kiniksa Pharmaceuticals released an investor...

2M ago

KNSA

Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth

Kiniksa Pharmaceuticals Ltd. Class A ( ($KNSA) ) has released its Q2 earnings. Here is a breakdown of...

3M ago

KNSA

Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth

Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q2 earnings call. Read on for the main highlights...

3M ago

KNSA

Kiniksa price target raised to $54 from $45 at Jefferies

Jefferies raised the firm’s price target on Kiniksa (KNSA) to $54 from $45 and keeps a Buy rating...

3M ago

KNSA

Kiniksa reports Q2 EPS 23c, consensus 26c

Reports Q2 revenue $156.8M, consensus $146.42M. “Our robust commercial performance in the second quarter was driven by expanding...

3M ago

KNSA

Kiniksa raises FY25 ARCALYST revenue view to $625M-$640M from $590M-$605M

Kiniksa (KNSA) expects 2025 ARCALYST net product revenue of between $625 million and $640 million, compared to prior...

3M ago

KNSA

KNSA Earnings this Week: How Will it Perform?

Kiniksa Pharmaceuticals Ltd. Class A (KNSA) is scheduled to report 2nd quarter earnings on 07/29/2025, before the market...

3M ago

KNSA

KNSA FAQ

What was Kiniksa Pharmaceuticals Ltd. Class A’s price range in the past 12 months?

Kiniksa Pharmaceuticals Ltd. Class A lowest stock price was $17.82 and its highest was $39.79 in the past 12 months.

What is Kiniksa Pharmaceuticals Ltd. Class A’s market cap?

Kiniksa Pharmaceuticals Ltd. Class A’s market cap is $2.88B.

When is Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date?

Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date is Nov 04, 2025 which is in 11 days.

How were Kiniksa Pharmaceuticals Ltd. Class A’s earnings last quarter?

Kiniksa Pharmaceuticals Ltd. Class A released its earnings results on Jul 29, 2025. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.01.

Is Kiniksa Pharmaceuticals Ltd. Class A overvalued?

According to Wall Street analysts Kiniksa Pharmaceuticals Ltd. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kiniksa Pharmaceuticals Ltd. Class A pay dividends?

Kiniksa Pharmaceuticals Ltd. Class A does not currently pay dividends.

What is Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate?

Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate is 0.32.

How many shares outstanding does Kiniksa Pharmaceuticals Ltd. Class A have?

Kiniksa Pharmaceuticals Ltd. Class A has 43,472,927 shares outstanding.

What happened to Kiniksa Pharmaceuticals Ltd. Class A’s price movement after its last earnings report?

Kiniksa Pharmaceuticals Ltd. Class A reported an EPS of $0.23 in its last earnings report, beating expectations of $0.22. Following the earnings report the stock price went up 12.315%.

Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals Ltd. Class A?

Currently, no hedge funds are holding shares in KNSA

Kiniksa Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

1.03%

Trailing 12-Months

Asset Growth

21.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kiniksa Pharmaceuticals Ltd. Class A

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals (KNSA) Earnings & Revenues

Historic Earnings Reports

KNSA Company Deck

KNSA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call was largely positive, with significant revenue growth for ARCALYST, successful milestone achievements, and promising pipeline developments. However, there is some competitive pressure and uncertainty regarding future patient retention strategies.View all KNSA earnings summaries

KNSA Stock 12 Month Forecast

Average Price Target

$50.43

▲(30.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","61":"$61","28.75":"$28.8","39.5":"$39.5","50.25":"$50.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,28.75,39.5,50.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.64,40.283076923076926,41.926153846153845,43.56923076923077,45.21230769230769,46.855384615384615,48.49846153846154,50.14153846153846,51.784615384615385,53.42769230769231,55.07076923076923,56.713846153846156,58.35692307692308,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.64,39.54692307692308,40.45384615384616,41.36076923076923,42.26769230769231,43.174615384615386,44.081538461538464,44.988461538461536,45.895384615384614,46.80230769230769,47.70923076923077,48.61615384615385,49.52307692307692,{"y":50.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.64,39.05230769230769,39.464615384615385,39.87692307692308,40.28923076923077,40.70153846153846,41.113846153846154,41.526153846153846,41.93846153846154,42.35076923076923,42.76307692307692,43.175384615384615,43.58769230769231,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.78,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >